NAVIGATOR: Study design

1
NAVIGATOR Study design
Nateglinide and Valsartan in Impaired Glucose
Tolerance Outcomes Research
N 9150 with IGT50 years with prior CV disease
or55 years with CV risk factorsRandomized,
double-blind 2 2 factorial design
Valsartan vs placebo AND Nateglinide vs placebo
Primary end pointsCV events, new-onset diabetes
NAVIGATOR Trial Steering Committee. Diabetes.
200352(suppl 1)A505.Skyler JS. Clin Diabetes.
200422162-6.
Insulin secretagogue